Effectiveness and Safety of Combination Mifepristone/Misoprostol for Medical Abortion

Primary Objectives:

* Effectiveness of mifepristone-misoprostol for medical abortion at or prior to 63 days gestational age, defined as complete abortion without further intervention within 14 days of mifepristone administration * Safety of mifepristone-misoprostol for medical abortion at or prior to 63 days gestational age, defined as the rate of significant Treatment Emergent Adverse Events (TEAE) as a composite outcome of the following events: 1. Hospital Admission; 2. Treatment in Emergency Room; 3. Blood Transfusion; 4. Infection requiring IV Antibiotics, Admission, or Surgical debridement; 5. Death; 6. Ongoing intrauterine pregnancy; 7. Ectopic pregnancy.

Secondary objectives:

* To determine the rate of ongoing pregnancy within 14 days after the administration of mifepristone * To determine the rate of surgical aspiration performed at the follow-up and time since mifepristone administration * To determine the reasons for surgical aspiration * To evaluate the follow-up rate * To evaluate the delay between the scheduled and actual treatment administration * To determine the overall safety profile of mifepristone-misoprostol combination * To evaluate the impact of the demographic characteristics (prescription site, region, gestational age) on effectiveness and safety * To evaluate the impact of gestational age on effectiveness and safety * To evaluate the impact of treatment self-administration on effectiveness and safety * To evaluate the impact of the method and timing of determining gestational age on effectiveness and safety

Study population:

Study performed on a stratified sample of sequential participants (n=3,000) who fulfill trial selection criteria and provide informed consent across a range of clinical practices in Canada (n=30)